Covid cases rise in DC, WHO advised against the use of Remdesivir

Daniel Fowler
November 20, 2020

Global experts with the World Health Organization (WHO) said on Friday that the anti-viral drug remdesivir shouldn't be used to treat hospitalized patients with COVID-19, regardless of "disease severity".

The WHO Guideline Development Group (GDG) based its recommendation on a new evidence review comparing the effects of several drug treatments on more than 7,000 patients hospitalised with COVID-19 in four worldwide randomised trials.

"We are disappointed the WHO guidelines appear to ignore this evidence at a time when cases are dramatically increasing around the world and doctors are relying on Veklury as the first and only approved antiviral treatment for patients with COVID-19".

In October, the World Health Organization said its global Solidarity trial using remdesivir in the hospital treatment of COVID-19 had found it had little to no effect on the length of time patients spent in hospital or their survival.

After reviewing the evidence, the panel concluded that remdesivir has no meaningful effect on death rates or other important outcomes for patients.

The recommendation may raise further questions about whether the European Union will need the 500,000 courses of the antiviral worth 1 billion euros it ordered last month. Additionally, the US FDA notably puts a massive trust in Remdesivir after granting a broad emergency authorization for its use.

European Central Bank plans for return of fans next summer
However, with England due to play Sri Lanka and India around the same time, a second squad would be required. He said that we are ready to host South Africa in January-February 2021 as part of the Future Tour Program.

The recommendation against remdesivir was based on data from four randomized trials including 7,333 people hospitalized with Covid-19.

Publishing updated treatment guidance in the BMJ medical journal, the panel acknowledged that their recommendation does not mean that remdesivir has no benefit for patients. Japan's chief cabinet secretary, Katsunobu Kato, said Friday there's no need for the nation, which gave its nod in May, to review remdesivir's approval at this time.

"Especially given the costs and resource implications associated with remdesivir. the panel felt the responsibility should be on demonstrating evidence of efficacy, which is not established by the current available data", the GDG said in its non-binding report.

As many as 50 countries have authorised the use of remdesivir to treat coronavirus.

The WHO noted that the evidence did not prove that remdesivir has no benefit but rather, there is no evidence based on now available data that it does improve important patient outcomes. Trump repeatedly touted the drug early in the pandemic, though medical evidence was lacking to support his claims.

Other reports by

Discuss This Article